Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL17964267 | 0.93 | PTGS1 (0.38) | CA1CA2PTGS1HSD17B1GAA | |
| Methyl Alcohol SCHEMBL27301818 | 0.87 | CA1 (0.41) | CA1CA2PTGS1GAACYP3A4 | |
| SCHEMBL7196734 | 0.87 | ALDH1A1 (0.35) | CA1CA2PTGS1GAACYP3A4 | |
| SCHEMBL9905202 | 0.84 | PTGS1 (0.36) | CA1CA2PTGS1ALDH1A1TDP1 | |
| Ammonia Solution, Strong SCHEMBL5027721 | 0.84 | — | — | |
| Phosphine SCHEMBL7200715 | 0.84 | — | — | |
| SCHEMBL6139750 | 0.82 | CA1 (0.38) | CA1CA2GAACYP3A4ALDH1A1 | |
| Acetaldehyde SCHEMBL6632642 | 0.80 | TSHR (0.31) | CA1CA2CYP3A4ALDH1A1TP53 | |
| SCHEMBL6853752 | 0.78 | — | — | |
| Acetonitrile SCHEMBL8083265 | 0.75 | ALDH1A1 (0.31) | CA1CA2CYP3A4ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | APALENE TECHNOLOGY CO., LTD. (HANGZHOU) (CN) | 2019-10-15 | — | — | US | disclosed |
| US-20180147571-A1 | NOVEL LINEAR ALPHA-OLEFIN CATALYSTS AND PREPARATION AND USE THEREOF | APALENE TECHNOLOGY CO., LTD. (JIAXING) (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147571-A1 | NOVEL LINEAR ALPHA-OLEFIN CATALYSTS AND PREPARATION AND USE THEREOF | UBE2L3, RNF168, AGL | CA1 2739/4885CA2 2863/4885PTGS1 2812/4885 |
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | UBE2L3, COG8, ACSL3 | CA1 2689/4885CA2 2807/4885PTGS1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.